Results 41 to 50 of about 87,925 (315)
Leukemia, 2016 In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than ...
A. Hochhaus +16 more
semanticscholar +1 more source
Turkish Journal of Hematology, 2012 The outcome in patients with chronic myeloid leukemia (CML) has dramatically improved over the last decade due to the widespread use of novel tyrosine kinase inhibitors such as imatinib. As overall survival has improved, the number of women with CML that wish to become pregnant has increased.
Debbie Jafta, Michael J Webb
openaire +4 more sources
PLoS ONE, 2021 BackgroundVascular endothelial dysfunction is an essential part of the pathophysiology of type 2 diabetes and its complications. In type 2 diabetes, endothelial dysfunction is characterized by reduced insulin signaling and increased transendothelial ...
Camiel V J Box +6 more
doaj +1 more source
Billion-years old proteins show the importance of N-lobe orientation in Imatinib-kinase selectivity [PDF]
arXiv, 2023 The molecular origins of proteins' functions are a combinatorial search problem in the proteins' sequence space, which requires enormous resources to solve. However, evolution has already solved this optimization problem for us, leaving behind suboptimal solutions along the way. Comparing suboptimal proteins along the evolutionary pathway, or ancestors,
arxiv
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
New England Journal of Medicine, 2002 BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.
H. Kantarjian +31 more
semanticscholar +1 more source
Frontiers in Systems Neuroscience, 2022 Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-α, -β, stem cell factor receptor (c-KIT), and BCR-ABL.
Megan Perkins +4 more
doaj +1 more source
Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. [PDF]
PLoS ONE, 2014 Imatinib, a targeted tyrosine kinase inhibitor, is the gold standard for managing chronic myeloid leukemia (CML). Despite its wide application, imatinib resistance occurs in 20-30% of individuals with CML.
Steven Bhutra +4 more
doaj +1 more source
The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design [PDF]
arXiv, 2023 Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are driving the substantial levels of non-adherence observed in this population.
arxiv
Turkish Journal of Hematology, 2013 Imatinib is a signal transduction regulator that selectively inhibits the tyrosine kinase family, including bcr-abl and c-kit, and the platelet-derived growth factor (PDGF) receptor. It is currently the fi rst-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients [1].
Atalay, Figen +2 more
openaire +5 more sources